Biologics (CD40 targeting)
CD40 targeting biologics (antagonistic/agonistic = inflammatory disorder/cancer)
Negotiable Min Order Quantity Unit
- Required Quantity
- Place of Origin
- South Korea
- Payment Terms
- Production method
- Shipping / Lead Time
- Negotiable / Negotiable
|Product name||Biologics (CD40 targeting)||Certification||-|
|Keyword||cancer , cd40 , biologics , autoimmune disease||Unit Size||-|
|Brand name||-||Unit Weigh||-|
|Supply type||Available,ODM||HS code||-|
PB Immune Therapeutics is biotech company founded in 2021 and located in Seoul, South Korea focusing on developing immunomodulatory therapeutics including monoclonal antibodies and cell therapies for treatment of autoimmune diseases. It is the culmination of over 16 years of dedicated research and over $36.5M in Korean government research funding in the field of xenotransplantation led by our CEO, Dr. Chung Gyu Park, MD, PhD. Through our research we have come to understand the key mechanisms in regulating and controlling the immune system through the CD40-CD40L axis and regulatory T cells. We were able to successfully treat diabetes in monkeys via xenotransplantation of pig liver cells with improved efficacy over currently available immunosuppressants.
Our company integrates two main platforms: our drug discovery platform using state-of-the-art technologies recently listed in the journal Nature as “Method of the Year,” which combined with immunological, technical and disease expertise can efficiently find promising drug targets and our drug testing platform using our non-human primate testing platform for more efficient drug screening and a higher chance of success and translatability to humans.
Our lead product is PB101, which is a monoclonal antibody targeting CD40 for treatment of multiple sclerosis (MS). Treatment of various autoimmune disorders including MS and pemphigus vulgaris (PV) involve systemically wiping out the immune system, leading to high cytotoxic side effects and substantially increased risk of infection. Our solution, PB101, has been proved to significantly reduce clinical symptoms, improve motor and cognitive function and reduction of MS biomarker in our monkey model.
Our goal is to out-license our PB101 asset to a pharmaceutical company with global outreach as we believe our product can significantly improve the quality of life and resolve some of the major unmet needs of patients with MS and other autoimmune diseases.
In order to do so, we are looking to secure funding by venture capital or strategic investors for further development and testing of PB101 and to prepare for human clinical trials. We are also interested in out-licensing our PB101 asset to pharmaceutical companies at the pre-clinical stage. This funding will also be used to test PB101 in other autoimmune disease contexts and for further development of our other antibody and regulatory T cell therapy products for treatment of various autoimmune diseases and certain cancers.
We are also willing to partner with accelerators who can help grow out our business and are also actively looking for academic and industry collaborators with expertise in antibody production, cell therapy development, and/or clinical trials for joint research.
Best in Class anti-CD40 monoclonal antibody targetting Multiple Sclerosis, Anti-drug antibody and Bullous disease
|Price (FOB)||Negotiable||transportation||Express,Ocean Shipping|
|Payment Options||L/C,Others||Shipping time||Negotiable|
- Chung gyu, Park
- #230, 71, Ihwajang-gil,, Jongno-gu, Seoul, Korea
- Product Category
- Year Established
- No. of Total Employees
- Company introduction
- Main Markets
- Main Product